24/7 Market News Snapshot 30 June, 2025 – Artelo Biosciences, Inc. Common Stock (NASDAQ:ARTL)

June 30, 2025

DENVER, Colo., 30 June, 2025 (www.247marketnews.com) – (NASDAQ:ARTL) are discussed in this article.
Artelo Biosciences, Inc. (ARTL) is currently experiencing a remarkable surge in its stock price, reflecting a 164.96% increase as it reached $17.991 in pre-market trading compared to the previous close of $6.790. This spike indicates heightened investor confidence, characterized by significant trading volume, with over 3.04 million shares exchanged. The market sentiment surrounding ARTL has turned notably bullish, prompting keen attention from traders and investors who are watching for further potential gains as the company’s innovative advancements continue to attract interest.

Concurrently, Artelo is making significant strides in the clinical development of ART26.12, the first oral Fatty Acid Binding Protein 5 (FABP5) inhibitor tested in humans. The initial results from a Phase 1 Single Ascending Dose study, which involved 49 healthy volunteers, demonstrated promising safety and pharmacokinetic profiles for ART26.12, reinforcing its potential as a groundbreaking treatment for pain management. Importantly, all reported adverse events were mild and transient, with no drug-related adverse events identified, and no safety signals detected across comprehensive assessments.

Dr. Andrew Yates, Senior Vice President and Chief Scientific Officer at Artelo, expressed optimism regarding these findings, viewing them as validation of the safety and pharmacokinetic data observed in preclinical studies. Given its innovative mechanism of action, ART26.12 addresses a significant unmet need for non-opioid pain therapies in a market projected to exceed $159 billion by 2030. A Multiple Ascending Dose study is expected to commence in the fourth quarter, further advancing ART26.12’s clinical journey and positioning Artelo as a leader in addressing the urgent needs of pain management in healthcare.

Related news for (ARTL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.